期刊
CURRENT NEUROPHARMACOLOGY
卷 21, 期 5, 页码 1224-1240出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1570159X20666220915091022
关键词
Advances; dopamine (DA) agonists; motor symptoms; non-motor symptoms; Parkinson's disease; treatment
Dopamine (DA) agonists are excellent dopamine replacement therapy for Parkinson's disease (PD) patients and are crucial in controlling motor and non-motor symptoms. Each DA agonist has unique characteristics, efficacy, and safety profile. Understanding DA agonists helps clinicians balance clinical efficacy and side effects.
Dopamine (DA) agonists, as an excellent dopamine replacement therapy for patients with early and advanced Parkinson's disease (PD), play a vital role in controlling motor and several non-motor symptoms. Besides, the application of DA agonists may delay levodopa therapy and the associated risk of motor complications. Indeed, each DA agonist has unique pharmacokinetic and pharmacodynamic characteristics and therefore has different therapeutic efficacy and safety profile. The comorbidities, significant non-motor manifestations, concomitant medications, and clinical features of PD individuals should guide the selection of a specific DA agonist to provide a more patient-tailored treatment option. Thorough knowledge of DA agonists helps clinicians better balance clinical efficacy and side effects. Therefore, this review refers to recent English-written articles on DA agonist therapy for PD patients and summarizes the latest findings on non-ergot DA agonists as well as the advantages and disadvantages of each compound to help clinicians in the selection of a specific DA agonist. In addition, novel D1/D5 partial agonists and new formulations of DA agonists are also discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据